# Aumolertinib

Source: https://onco.cc/drugs/aumolertinib/  
OnCo record `aumolertinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial.

## Summary

Approved by the NMPA in March 2020 for EGFR T790M-positive NSCLC after prior EGFR inhibitors and in December 2021 for first-line EGFR-mutant NSCLC on AENEAS (429 patients: median progression-free survival 19.3 versus 9.9 months with gefitinib, hazard ratio 0.46). It has become one of the most prescribed targeted drugs in China after NRDL listing and is under evaluation in Europe. Hansoh is testing it after chemoradiotherapy in stage III disease and in combination regimens.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Also known as: Aumseqa; Almonertinib
- Tags: china
- Brand: Ameile
- Code: HS-10296, almonertinib
- Modality: Small-molecule third-generation EGFR TKI
- Mechanism: Irreversible third-generation EGFR inhibitor selective for sensitising and T790M mutations over wild-type EGFR; a cyclopropyl modification of the osimertinib scaffold.
- Approvals: China 2020: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy; China 2021: First-line EGFR exon 19 deletion or L858R NSCLC (AENEAS); EU 2026: Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Almonertinib
- Hansoh Pharma (page moved; nearest live section): https://www.hspharm.com/
- AENEAS (J Clin Oncol 2022): https://doi.org/10.1200/JCO.21.02641
- NMPA (National Medical Products Administration): https://www.nmpa.gov.cn

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- terms: [EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)](https://onco.cc/terms/egfr-mutation-subtypes/)
- trials: [A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06474455/), [A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct04951635/), [A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC](https://onco.cc/trials/nct07183189/), [AENEAS](https://onco.cc/trials/aeneas/), [Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance](https://onco.cc/trials/nct06043973/), [Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations](https://onco.cc/trials/nct04687241/), [Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer](https://onco.cc/trials/nct05800223/), [Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut](https://onco.cc/trials/nct04923906/), [Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com](https://onco.cc/trials/nct04762459/), [MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)](https://onco.cc/trials/nct04841811/), [Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05503888/)

---
JSON: https://onco.cc/api/v1/entities/aumolertinib.json